
Please try another search
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Michael G. Kaplitt | - | - | Member of Scientific Advisory Board |
Nicole Seligman | 67 | 2019 | Independent Director |
Gregory A. Petsko | - | - | Chairman of Scientific Advisory Board |
Keith Reginald Harris | 70 | 2015 | Independent Chairman of the Board |
Arnold J. Levine | 83 | 2016 | Member of Scientific Advisory Board |
Alexandria Forbes | 58 | 2015 | CEO, President & Director |
Thomas E. Shenk | 76 | 2015 | Independent Director & Member of Scientific Advisory Board |
Neil Mendoza | 63 | 2015 | Independent Director |
Ellen Hukkelhoven | 36 | 2017 | Director |
James C. Alwine | - | - | Member of Scientific Advisory Board |
Kevin Weeks | - | - | Member of Scientific Advisory Board |
Stefano Rivella | - | - | Member of Scientific Advisory Board |
Chuan He | 52 | - | Member of Scientific Advisory Board |
Robert Batey | - | - | Member of Scientific Advisory Board |
Jiuyun Yu | 59 | 2022 | Independent Director |
Lynne Elizabeth Maquat | - | 2019 | Member of Scientific Advisory Board |
Brian Shoichet | - | - | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review